Maravai LifeSciences Holdings, Inc. (MRVI) vs SELLAS Life Sciences Group, Inc. (SLS)
A side-by-side comparison of Maravai LifeSciences Holdings, Inc. and SELLAS Life Sciences Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MRVI
Maravai LifeSciences Holdings, Inc.
$7.96HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
SLS
SELLAS Life Sciences Group, Inc.
$11.45HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — MRVI vs SLS
growth of $100 · dividends reinvested · last 6yMRVI -71.5% (-18.9%/yr)SLS +327.5% (+27.4%/yr)SLS compounded faster over this window
Log scale — wide-divergence pair
MRVI SLS
MRVI vs SLS: by the numbers
- •MRVI is the larger company ($2.20B vs $2.13B market cap).
- •Both run net losses; SLS's is the smaller (0.00% vs -37.07% net margin).
Metrics side by side
Valuation
| Metric | MRVI | SLS |
|---|---|---|
| P/S ratio | 10.53 | N/A |
| P/B ratio | 10.74 | 15.47 |
| EV / EBITDA | 15.22 | N/A |
Profitability
| Metric | MRVI | SLS |
|---|---|---|
| Gross margin | 17.98% | 0.00% |
| Operating margin | -3.63% | 0.00% |
| Net margin | -37.07% | 0.00% |
| ROE | -37.82% | -23.58% |
| ROIC | 16.96% | -25.45% |
Growth (annualized)
| Metric | MRVI | SLS |
|---|---|---|
| Revenue CAGR (5Y) | -17.68% | N/A |
| Total return CAGR (5Y) | -27.63% | 6.20% |
Frequently asked
- How have MRVI and SLS total returns compared?
- Over the past 5 years, MRVI delivered -27.63% and SLS delivered 6.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.